NeuroSigma has secured FDA approval to start a Phase III clinical trial investigating the Monarch eTNS system for treatment of epilepsy. The device transmits an electrical pulse to the patient through a soft patch attached to the forehead. PET imaging confirmed the treatment targets epilepsy-affected regions. The company plans to conduct multicenter trials in the U.S., Europe and Canada.

Related Summaries